Scientists Finally Reveal How This Alzheimer’s Drug Really Works

Why It Matters

Understanding lecanemab’s Fc‑mediated microglial activation clarifies why the drug slows cognitive decline and informs the development of more effective, lower‑risk Alzheimer’s treatments.

Key Takeaways

• Fc fragment essential for lecanemab efficacy.
• Microglia activation drives amyloid plaque clearance.
• Humanized mouse model confirmed antibody‑microglia interaction.
• Findings guide next‑gen Alzheimer’s therapies without antibodies.
• Gene SPP1 marks active plaque‑clearing microglia.

Pulse Analysis

Alzheimer’s disease remains the most prevalent neurodegenerative disorder, affecting over 55 million people worldwide. The accumulation of amyloid‑beta plaques has long been considered a primary driver of neuronal loss, prompting the development of anti‑amyloid antibodies such as lecanemab, which received FDA approval in 2023. While clinical trials demonstrated modest slowing of cognitive decline, the precise biological pathway through which lecanemab exerts its benefit has been debated. Clarifying this mechanism is critical for improving efficacy, reducing adverse events, and justifying the high cost of antibody‑based therapies.

The VIB‑KU Leuven team resolved the controversy by pinpointing the antibody’s Fc fragment as the essential effector domain. In a sophisticated mouse model grafted with human microglia, intact lecanemab bound amyloid plaques and simultaneously presented its Fc region to microglial Fc receptors, triggering a transcriptional program dominated by SPP1 expression. This program amplified phagocytosis and lysosomal degradation, effectively clearing plaques. When the Fc portion was genetically removed, microglia remained quiescent and plaque burden persisted, providing direct causal evidence that microglial activation, not mere plaque binding, drives therapeutic benefit.

The discovery reshapes the roadmap for Alzheimer’s drug design. By confirming that Fc‑mediated microglial engagement is both necessary and sufficient for plaque removal, pharmaceutical developers can engineer antibodies with optimized Fc signaling or explore small‑molecule agents that directly stimulate the identified microglial program. Such strategies promise to retain efficacy while mitigating infusion‑related side effects and the high manufacturing costs of full‑length antibodies. Moreover, the identified SPP1‑rich microglial signature offers a biomarker for patient stratification and early‑phase trial readouts, accelerating the pipeline for next‑generation neurodegenerative therapeutics.